The orphan receptor GPR35 contributes to angiotensin II–induced hypertension and cardiac dysfunction in mice

Divorty, N., Milligan, G. , Graham, D. and Nicklin, S. A. (2018) The orphan receptor GPR35 contributes to angiotensin II–induced hypertension and cardiac dysfunction in mice. American Journal of Hypertension, 31(9), pp. 1049-1058. (doi: 10.1093/ajh/hpy073) (PMID:29860395) (PMCID:PMC6077831)

161561.pdf - Published Version
Available under License Creative Commons Attribution.



BACKGROUND: The orphan receptor G protein–coupled receptor 35 (GPR35) has been associated with a range of diseases, including cancer, inflammatory bowel disease, diabetes, hypertension, and heart failure. To assess the potential for GPR35 as a therapeutic target in cardiovascular disease, this study investigated the cardiovascular phenotype of a GPR35 knockout mouse under both basal conditions and following pathophysiological stimulation. METHODS: Blood pressure was monitored in male wild-type and GPR35 knockout mice over 7–14 days using implantable telemetry. Cardiac function and dimensions were assessed using echocardiography, and cardiomyocyte morphology evaluated histologically. Two weeks of angiotensin II (Ang II) infusion was used to investigate the effects of GPR35 deficiency under pathophysiological conditions. Gpr35 messenger RNA expression in cardiovascular tissues was assessed using quantitative polymerase chain reaction. RESULTS: There were no significant differences in blood pressure, cardiac function, or cardiomyocyte morphology in GPR35 knockout mice compared with wild-type mice. Following Ang II infusion, GPR35 knockout mice were protected from significant increases in systolic, diastolic, and mean arterial blood pressure or impaired left ventricular systolic function, in contrast to wild-type mice. There were no significant differences in Gpr35 messenger RNA expression in heart, kidney, and aorta following Ang II infusion in wild-type mice. CONCLUSIONS: Although GPR35 does not appear to influence basal cardiovascular regulation, these findings demonstrate that it plays an important pathological role in the development of Ang II–induced hypertension and impaired cardiac function. This suggests that GPR35 is a potential novel drug target for therapeutic intervention in hypertension.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Graham, Dr Delyth and Nicklin, Professor Stuart and Divorty, Nina and Milligan, Professor Graeme
Authors: Divorty, N., Milligan, G., Graham, D., and Nicklin, S. A.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
College of Medical Veterinary and Life Sciences > School of Molecular Biosciences
Journal Name:American Journal of Hypertension
Publisher:Oxford University Press
ISSN (Online):1941-7225
Published Online:31 May 2018
Copyright Holders:Copyright © 2018 The Authors
First Published:First published in American Journal of Hypertension 31(9): 1049-1058
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
615961Molecular Functions in Disease (PhD Studentship 2012-2016)Graeme MilliganWellcome Trust (WELLCOTR)099787/Z/12/ZRI MOLECULAR CELL & SYSTEMS BIOLOGY
617771BHF centre of excellenceRhian TouyzBritish Heart Foundation (BHF)RE/13/5/30177RI CARDIOVASCULAR & MEDICAL SCIENCES